2013, Colección Sociología. Personas, organizaciones, sociedad, ISBN 9569320540, 329
Book
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 121 - 130
Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk...
MEDICINE, GENERAL & INTERNAL | BASE-LINE | EVENTS | EFFICACY | SAFETY | PEPTIDE-1 RECEPTOR AGONISTS | Myocardial infarction | Heart attacks | Peptides | Control methods | Glucagon | Clinical trials | Cardiovascular disease | Population studies | Cancer therapies | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Glucagon-like peptide 1 | Women | Cerebral infarction | Enzymes | Stroke | Middle age | Diabetes mellitus | Health risks | Hypoglycemia | Risk analysis | Angina pectoris | Disease control | Cholesterol | Thyroid cancer | Agonists | Diabetes | Cardiovascular diseases | Health risk assessment | Elderly
MEDICINE, GENERAL & INTERNAL | BASE-LINE | EVENTS | EFFICACY | SAFETY | PEPTIDE-1 RECEPTOR AGONISTS | Myocardial infarction | Heart attacks | Peptides | Control methods | Glucagon | Clinical trials | Cardiovascular disease | Population studies | Cancer therapies | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Glucagon-like peptide 1 | Women | Cerebral infarction | Enzymes | Stroke | Middle age | Diabetes mellitus | Health risks | Hypoglycemia | Risk analysis | Angina pectoris | Disease control | Cholesterol | Thyroid cancer | Agonists | Diabetes | Cardiovascular diseases | Health risk assessment | Elderly
Journal Article
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 131 - 138
Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the...
MEDICINE, GENERAL & INTERNAL | BASE-LINE | LIRAGLUTIDE | INCRETIN | CARDIOVASCULAR OUTCOMES | DISEASE | Myocardial infarction | Therapy | Peptides | Glucagon | Cardiovascular disease | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Urine | Creatinine | Cerebral infarction | Stroke | Kidneys | Epidermal growth factor receptors | Diabetes mellitus | Health risks | Risk analysis | Disease control | Agonists | Microvasculature | Diabetes | Kidney diseases | Renal replacement therapy | Gastrointestinal surgery | Cardiovascular diseases | Health risk assessment
MEDICINE, GENERAL & INTERNAL | BASE-LINE | LIRAGLUTIDE | INCRETIN | CARDIOVASCULAR OUTCOMES | DISEASE | Myocardial infarction | Therapy | Peptides | Glucagon | Cardiovascular disease | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Urine | Creatinine | Cerebral infarction | Stroke | Kidneys | Epidermal growth factor receptors | Diabetes mellitus | Health risks | Risk analysis | Disease control | Agonists | Microvasculature | Diabetes | Kidney diseases | Renal replacement therapy | Gastrointestinal surgery | Cardiovascular diseases | Health risk assessment
Journal Article
5.
Full Text
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy, ISSN 1554-8627, 01/2016, Volume 12, Issue 1, pp. 1 - 222
stress | chaperone-mediated autophagy | vacuole | autolysosome | macroautophagy | flux | autophagosome | LC3 | lysosome | phagophore | Phagophore | Lysosome | Autolysosome | Flux | Autophagosome | Vacuole | Chaperonemediated autophagy |